Leuven (BELGIUM) – September 20, 2012 – TiGenix (Euronext Brussels: TIG) announced
today that the Company has appointed Jean Stéphenne as independent director and new
chairman of the Company’s board of directors, and Russell Greig as independent director,
in replacement of Koenraad Debackere and Mounia Chaoui-Roulleau, who resigned from
the board. Former chairman Willy Duron will remain an independent board member.

“We are delighted and proud to appoint these seasoned professionals, who both have an
outstanding record in the pharmaceutical industry,” said Willy Duron, former chairman of the
Board of Directors. “Their long and broad experience with all aspects of drug development
and building innovative pharmaceutical and biotechnology companies will be of immense
value as TiGenix enters into a pivotal phase of its growth with the commercial roll-out of
ChondroCelect and the advanced clinical development of its cell therapy programs. The
board would like to express its gratitude to Koenraad Debackere and Mounia Chaoui-
Roulleau for their expert guidance and support through the years.”

Jean Stéphenne :
Jean Stéphenne was until recently Member of the Corporate Executive Team of
GlaxoSmithKline (GSK), and Chairman and President of GSK Biologicals in Wavre,
Belgium, which he built into a world leader in vaccines. He currently serves as Chairman of
BESIX, IBA and BioWin, and as Director of BNP Paribas Fortis, VBO/FEB, Groupe
Bruxelles Lambert (GBL), and Vesalius Biocapital. 

Russell G. Greig, PhD :
Russell Greig worked at GlaxoSmithKline for nearly three decades, most recently as
President of SR One, GSK’s Corporate Venture Group. Prior to joining SR One, he served
as President of GSK’s Pharmaceuticals International from 2003 to 2008 and also on the
GSK Corporate Executive Team. Dr Greig currently serves as Chairman of AM Pharma in
the Netherlands, Isconova AB in Sweden and Syntaxin in the UK, and is a member of the
Scottish Science Advisory Council. 

The appointments of Jean Stéphenne and Russell Greig are effective immediately subject
to final appointment by the next shareholders’ meeting.